What is the treatment for Cannabinoid Hyperemesis Syndrome (CHS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The most effective treatment for cannabinoid hyperemesis syndrome (CHS) is complete cessation of cannabis use for at least 6 months, or at least equal to the total duration of 3 typical vomiting cycles in that patient, as this leads to resolution of symptoms.

Key Treatment Strategies

  • Cannabis cessation is the primary treatment for long-term resolution of symptoms, with a recommended abstinence period of at least 6 months, or at least equal to the total duration of 3 typical vomiting cycles in that patient, as supported by the 2024 study published in Gastroenterology 1.
  • For acute and short-term care, topical capsaicin, benzodiazepines, haloperidol, promethazine, olanzapine, and ondansetron may be used, with topical capsaicin (0.1%) cream being a potential option for symptom improvement, as noted in the same study 1.
  • Opioids should be avoided due to the risk of worsening nausea and high risk of addiction, as cautioned in the study 1.
  • For long-term management, counseling to achieve marijuana cessation and tricyclic antidepressants, such as amitriptyline, are the mainstay of therapy, with a minimal effective dose of 75–100 mg at bedtime, starting at 25 mg and titrating the dose with increments each week to reach minimal effective dose, as recommended in the study 1.

Additional Considerations

  • The clinical approach in the emergency department (ED) requires immediate evaluation for life-threatening disorders, such as acute abdomen, bowel obstruction, mesenteric ischemia, pancreatitis, and myocardial infarction, among others, as highlighted in the study 1.
  • Differential diagnosis in the outpatient setting after exclusion of structural abnormalities includes rumination syndrome, gastroparesis, CVS, pregnancy, migraine, and functional chronic nausea and vomiting syndrome, as noted in the study 1.

From the Research

Treatment Options for Cannabinoid Hyperemesis Syndrome

  • The primary treatment for cannabinoid hyperemesis syndrome (CHS) is cessation of cannabis use, as it is the only intervention that provides complete symptom relief 2, 3, 4.
  • Pharmacological management of CHS includes the use of analgesics, antiemetics, antipsychotics, beta blockers, and transient receptor potential vanilloid (TRPV) agonists 2.
  • Classic antiemetics may be tried initially but often fail to alleviate CHS, while antipsychotics such as haloperidol, benzodiazepines, and/or capsaicin cream appear to be the most efficacious in treating this unique disorder 2, 3, 5.
  • Topical capsaicin has been shown to be a promising intervention for CHS, providing dramatic relief within 24 hours in some cases 6, 4, 5.

Symptom Management

  • Symptom relief can be achieved through the use of hot showers and baths (hydrothermotherapy) 2, 3, 4.
  • Avoidance of opioids is recommended, as they may be harmful and lack evidence for effectiveness in treating CHS 3, 4.
  • Conventional antiemetics, including antihistamines, serotonin antagonists, dopamine antagonists, and benzodiazepines, may have limited effectiveness in treating CHS 3, 4.

Diagnosis and Treatment Guidelines

  • A novel treatment guideline has been established to unite the emergency department community in the treatment of CHS, focusing on symptom relief, education on cannabis cessation, and avoidance of unnecessary opioids 3.
  • Directed questions about cannabis use and the effect of hydrothermotherapy on CHS symptoms can frequently confirm the diagnosis, enabling appropriate pharmacotherapy and referral to addiction treatment 2.
  • Clinicians and public health officials should identify and treat CHS patients with strategies that decrease exposure to opioids, minimize use of healthcare resources, and maximize patient safety 3, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.

Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2017

Research

Topical Capsaicin for Treating Cannabinoid Hyperemesis Syndrome.

Case reports in gastrointestinal medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.